FDA hands ac­cel­er­at­ed nod to Seagen, Gen­mab's so­lo ADC in cer­vi­cal can­cer, but com­bo stud­ies look even more promis­ing

Bio­phar­ma’s res­i­dent an­ti­body-drug con­ju­gate ex­pert Seagen has scored a clutch of on­col­o­gy ap­provals in re­cent years, find­ing gold in what are known as “third-gen” AD­Cs. Now, an­oth­er of their part­nered con­ju­gates is ready for prime time.

The FDA on Mon­day hand­ed an ac­cel­er­at­ed ap­proval to Seagen and Gen­mab’s Tiv­dak (ti­so­tum­ab ve­dotin-tftv, or “TV”) in sec­ond-line pa­tients with re­cur­rent or metasta­t­ic cer­vi­cal can­cer who pre­vi­ous­ly pro­gressed af­ter chemother­a­py rather than PD-(L)1 sys­temic ther­a­py, the com­pa­nies said in a re­lease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.